E Fund Management Co. Ltd. Sells 3,341 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

E Fund Management Co. Ltd. reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 30.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,657 shares of the company’s stock after selling 3,341 shares during the period. E Fund Management Co. Ltd.’s holdings in Apellis Pharmaceuticals were worth $458,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. lifted its stake in shares of Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares during the period. Covestor Ltd lifted its position in shares of Apellis Pharmaceuticals by 564.2% in the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 29.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after purchasing an additional 687 shares during the last quarter. HC Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals during the fourth quarter worth $210,000. Finally, Whittier Trust Co. bought a new position in Apellis Pharmaceuticals during the fourth quarter worth $221,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Up 0.5 %

Shares of APLS stock traded up $0.22 during trading hours on Thursday, reaching $42.52. The company had a trading volume of 1,052,714 shares, compared to its average volume of 1,574,096. The company has a market cap of $5.16 billion, a price-to-earnings ratio of -12.29 and a beta of 0.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals, Inc. has a 12 month low of $19.83 and a 12 month high of $94.75. The business has a fifty day simple moving average of $54.30 and a 200-day simple moving average of $57.42.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. During the same period last year, the business earned ($1.56) EPS. The business’s revenue was up 284.3% on a year-over-year basis. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Citigroup decreased their price target on Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. UBS Group cut their price target on Apellis Pharmaceuticals from $89.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday. Robert W. Baird reissued an “outperform” rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Finally, Wedbush reduced their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $76.67.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Cedric Francois sold 250,000 shares of Apellis Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was sold at an average price of $64.11, for a total value of $16,027,500.00. Following the sale, the chief executive officer now owns 313,662 shares in the company, valued at $20,108,870.82. The disclosure for this sale can be found here. Insiders have sold 376,427 shares of company stock valued at $23,169,639 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).